A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk.
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis.
A species of GAMMARETROVIRUS causing leukemia, lymphosarcoma, immune deficiency, or other degenerative diseases in cats. Several cellular oncogenes confer on FeLV the ability to induce sarcomas (see also SARCOMA VIRUSES, FELINE).
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from spontaneous leukemia in AKR strain mice.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Disease having a short and relatively severe course.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.
The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.
Mapping of the KARYOTYPE of a cell.
A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.
A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).
Established cell cultures that have the potential to propagate indefinitely.
A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
A general term for various neoplastic diseases of the lymphoid tissue.
A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Immunological rejection of leukemia cells following bone marrow transplantation.
A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A receptor subunit that combines with CYTOKINE RECEPTOR GP130 to form the dual specificity receptor for LEUKEMIA INHIBITORY FACTOR and ONCOSTATIN M. The subunit is also a component of the CILIARY NEUROTROPHIC FACTOR RECEPTOR. Both membrane-bound and secreted isoforms of the receptor subunit exist due to ALTERNATIVE SPLICING of its mRNA. The secreted isoform is believed to act as an inhibitory receptor, while the membrane-bound form is a signaling receptor.
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A spectrum of disorders characterized by clonal expansions of the peripheral blood LYMPHOCYTE populations known as large granular lymphocytes which contain abundant cytoplasm and azurophilic granules. Subtypes develop from either CD3-negative NATURAL KILLER CELLS or CD3-positive T-CELLS. The clinical course of both subtypes can vary from spontaneous regression to progressive, malignant disease.
Examination of CHROMOSOMES to diagnose, classify, screen for, or manage genetic diseases and abnormalities. Following preparation of the sample, KARYOTYPING is performed and/or the specific chromosomes are analyzed.
Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
The return of a sign, symptom, or disease after a remission.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
Virus diseases caused by the RETROVIRIDAE.
Progenitor cells from which all blood cells derive.
A cell line derived from cultured tumor cells.
Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.
Transcriptional trans-acting proteins of the promoter elements found in the long terminal repeats (LTR) of HUMAN T-LYMPHOTROPIC VIRUS 1 and HUMAN T-LYMPHOTROPIC VIRUS 2. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the LTR.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Inorganic or organic compounds that contain arsenic.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
A species of GAMMARETROVIRUS causing leukemia in the gibbon ape. Natural transmission is by contact.
DNA present in neoplastic tissue.
A specific pair of GROUP G CHROMOSOMES of the human chromosome classification.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.
Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A neoplastic disease of cats frequently associated with feline leukemia virus infection.
A subdiscipline of genetics which deals with the cytological and molecular analysis of the CHROMOSOMES, and location of the GENES on chromosomes, and the movements of chromosomes during the CELL CYCLE.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS).
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A lymphoid neoplastic disease in cattle caused by the bovine leukemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukemia but the presence of malignant cells in the blood is not a consistent finding.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antibodies produced by a single clone of cells.
RNA present in neoplastic tissue.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Elements of limited time intervals, contributing to particular results or situations.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
The short, acrocentric human chromosomes, called group G in the human chromosome classification. This group consists of chromosome pairs 21 and 22 and the Y chromosome.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of >20% MAST CELLS, multi-organ failure and a short survival.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Cell surface receptors formed from the dimerization of LIF RECEPTOR ALPHA SUBUNIT with CYTOKINE RECEPTOR GP130. Although originally described as receptors for LEUKEMIA INHIBITORY FACTOR these receptors also bind the closely-related protein ONCOSTATIN M and are referred to as both LIF receptors and type I oncostatin M receptors.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from radiation-induced lymphomas in C57BL mice. It is leukemogenic, thymotrophic, can be transmitted vertically, and replicates only in vivo.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Agents that inhibit PROTEIN KINASES.
Duplex DNA sequences in eukaryotic chromosomes, corresponding to the genome of a virus, that are transmitted from one cell generation to the next without causing lysis of the host. Proviruses are often associated with neoplastic cell transformation and are key features of retrovirus biology.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Antimetabolites that are useful in cancer chemotherapy.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
A genus in the family RETROVIRIDAE consisting of exogenous horizontally-transmitted viruses found in a few groups of mammals. Infections caused by these viruses include human B- or adult T-cell leukemia/lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), and bovine leukemia (ENZOOTIC BOVINE LEUKOSIS). The type species is LEUKEMIA VIRUS, BOVINE.
A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.
Deoxyribonucleic acid that makes up the genetic material of viruses.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A method (first developed by E.M. Southern) for detection of DNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED).
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
The action of a drug in promoting or enhancing the effectiveness of another drug.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)
Nucleosides containing arabinose as their sugar moiety.
An anthracenedione-derived antineoplastic agent.
A genus of RETROVIRIDAE comprising endogenous sequences in mammals, related RETICULOENDOTHELIOSIS VIRUSES, AVIAN, and a reptilian virus. Many species contain oncogenes and cause leukemias and sarcomas.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The functional hereditary units of VIRUSES.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Proto-oncogene protein bcr is a serine-threonine kinase that functions as a negative regulator of CELL PROLIFERATION and NEOPLASTIC CELL TRANSFORMATION. It is commonly fused with cellular abl protein to form BCR-ABL FUSION PROTEINS in PHILADELPHIA CHROMOSOME positive LEUKEMIA patients.
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Tetracyclic spiro-BENZAZEPINES isolated from the seeds of CEPHALOTAXUS. They are esters of the alkaloid cephalotaxine and may be effective as antineoplastic agents.
An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. (1/3339)

Genotoxic stress triggers the activation of several sensor molecules, such as p53, JNK1/SAPK and c-Abl, and occasionally promotes the cells to apoptosis. We previously reported that JNK1/SAPK regulates genotoxic stress-induced apoptosis in p53-negative U937 cells by activating caspases. c-Abl is expected to act upstream of JNK1/SAPK activation upon treatment with genotoxic stressors, but its involvement in apoptosis development is still unclear. We herein investigated the kinase activities of c-Abl and JNK1/SAPK during apoptosis elicited by genotoxic anticancer drugs and tumor necrosis factor (TNF) in U937 cells and their apoptosis-resistant variant UK711 cells. We found that the activation of JNK1/SAPK and c-Abl correlated well with apoptosis development in these cell lines. Unexpectedly, however, the JNK1/SAPK activation preceded the c-Abl activation. Moreover, the caspase inhibitor Z-Asp suppressed c-Abl activation and the onset of apoptosis but not the JNK1/SAPK activation. Interestingly, c-Abl tyrosine kinase inhibition by CGP 57148 reduced apoptosis without interfering with JNK1/SAPK activation. These results indicate that c-Abl acts not upstream of JNK1/ SAPK but downstream of caspases during the development of p53-independent apoptosis and is possibly involved in accelerating execution of the cell death pathway.  (+info)

Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. (2/3339)

Arsenic exhibits a differential toxicity to cancer cells. At a high concentration (>5 microM), As2O3 causes acute necrosis in various cell lines. At a lower concentration (0.5-5 microm), it induces myeloid cell maturation and an arrest in metaphase, leading to apoptosis. As2O3-treated cells have features found with both tubulin-assembling enhancers (Taxol) and inhibitors (colchicine). Prior treatment of monomeric tubulin with As2O3 markedly inhibits GTP-induced polymerization and microtubule formation in vitro but does not destabilize GTP-induced tubulin polymers. Cross-inhibition experiments indicate that As2O3 is a noncompetitive inhibitor of GTP binding to tubulin. These observations correlate with the three-dimensional structure of beta-tubulin and suggest that the cross-linking of two vicinal cysteine residues (Cys-12 and Cys-213) by trivalent arsenic inactivates the GTP binding site. Furthermore, exogenous GTP can prevent As2O3-induced mitotic arrest.  (+info)

Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. (3/3339)

The receptor for the gene product of the obesity gene, leptin, was recently reported to be expressed on murine and human hematopoietic progenitor cells. Therefore, we studied the expression of the leptin receptor, OB-R, in normal myeloid precursors, human leukemia cell lines, and primary leukemic cells using reverse-transcriptase polymerase chain reaction. In normal hematopoiesis, OB-R was expressed in CD34(+) cells. Normal promyelocytes (CD34(-)33(+) and CD34(-)13(+)) expressed only very low levels of the short, presumably nonsignaling isoform. Both the long and short isoforms of OB-R were expressed in 10 of 22 samples from patients with newly diagnosed primary or secondary acute myeloid leukemia (AML), with a higher incidence of the long isoform in primary AML (87.6% v 28.6%; P =.01). The incidence of OB-R expression was higher in recurrent than in newly diagnosed AML (P <.001), and samples from four patients with refractory AML showed strong expression of both isoforms. Both OB-R isoforms were also expressed in newly diagnosed and recurrent acute promyelocytic leukemia cells but were essentially absent in samples of chronic or acute lymphocytic leukemia. In vitro growth of myeloid leukemic cell lines and of blasts from 14 primary AMLs demonstrated that recombinant human leptin alone induced low level proliferation, significantly (P <.05) increased proliferation induced by recombinant human granulocyte colony-stimulating factor, interleukin 3, and stem cell factor in a subset of AML and increased colony formation (P <.005). Also, leptin reduced apoptosis induced by cytokine withdrawal in MO7E and TF-1 cells. Serum leptin levels correlated only with body mass index (P <. 001) and gender (P =.03). Results confirm the reported expression of leptin receptor in normal CD34(+) cells and demonstrate the frequent expression of leptin receptors in AML blasts. While normal promyelocytes lack receptor expression, leukemic promyelocytes express both isoforms. We also demonstrate proliferative effects of leptin alone and in combination with other physiologic cytokines, and anti-apoptotic properties of leptin. These findings could have implications for the pathophysiology of AML.  (+info)

Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells. (4/3339)

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is an EGF family member expressed by numerous cell types that binds to EGF receptor 1 (HER-1) or 4 (HER-4) inducing mitogenic and/or chemotactic activities. Membrane-bound HB-EGF retains growth activity and adhesion capabilities and the unique property of being the receptor for diphtheria toxin (DT). The interest in studying HB-EGF in acute leukemia stems from these mitogenic, chemotactic, and receptor functions. We analyzed the expression of HB-EGF in L428, Raji, Jurkat, Karpas 299, L540, 2C8, HL-60, U937, THP-1, ML-3, and K562 cell lines and in primary blasts from 12 acute myeloid leukemia (AML) cases, by reverse-transcriptase polymerase chain reaction (RT-PCR) and Northern blot and by the evaluation of sensitivity to DT. The release of functional HB-EGF was assessed by evaluation of its proliferative effects on the HB-EGF-sensitive Balb/c 3T3 cell line. HB-EGF was expressed by all myeloid and T, but not B (L428, Raji), lymphoid cell lines tested, as well as by the majority (8 of 12) of ex vivo AML blasts. Cell lines (except for the K562 cell line) and AML blasts expressing HB-EGF mRNA underwent apoptotic death following exposure to DT, thus demonstrating the presence of the HB-EGF molecule on their membrane. Leukemic cells also released a fully functional HB-EGF molecule that was mitogenic for the Balb/c 3T3 cell line. Factors relevant to the biology of leukemic growth, such as tumor necrosis factor-alpha (TNF-alpha), 1alpha,25-(OH)2D3, and especially all-trans retinoic acid (ATRA), upregulated HB-EGF mRNA in HL-60 or ML-3 cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induced HB-EGF mRNA and acquisition of sensitivity to DT in one previously HB-EGF-negative leukemia case. Moreover, the U937 and Karpas 299 cell lines expressed HER-4 mRNA. This work shows that HB-EGF is a growth factor produced by primary leukemic cells and regulated by ATRA, 1alpha, 25-(OH)2D3, and GM-CSF.  (+info)

Systemic candidiasis with candida vasculitis due to Candida kruzei in a patient with acute myeloid leukaemia. (5/3339)

Candida kruzei-related systemic infections are increasing in frequency, particularly in patients receiving prophylaxis with antifungal triazoles. A Caucasian male with newly diagnosed acute myeloid leukaemia (AML M1) developed severe and persistent fever associated with a micropustular eruption scattered over the trunk and limbs during induction chemotherapy. Blood cultures grew Candida kruzei, and biopsies of the skin lesions revealed a candida vasculitis. He responded to high doses of liposomal amphotericin B and was discharged well from hospital.  (+info)

Differential expression and phosphorylation of CTCF, a c-myc transcriptional regulator, during differentiation of human myeloid cells. (6/3339)

CTCF is a transcriptional repressor of the c-myc gene. Although CTCF has been characterized in some detail, there is very little information about the regulation of CTCF activity. Therefore we investigated CTCF expression and phosphorylation during induced differentiation of human myeloid leukemia cells. We found that: (i) both CTCF mRNA and protein are down-regulated during terminal differentiation in most cell lines tested; (ii) CTCF down-regulation is retarded and less pronounced than that of c-myc; (iii) CTCF protein is differentially phosphorylated and the phosphorylation profiles depend on the differentiation pathway. We concluded that CTCF expression and activity is controlled at transcriptional and post-transcriptional levels.  (+info)

High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. (7/3339)

We explored the combination of busulfan/cyclophosphamide/etoposide as conditioning regimen prior to bone marrow transplantation in 31 patients with acute myeloid leukemia (AML) in first complete remission. The preparative regimen consisted of 16 mg/kg busulfan, 30-60 mg/kg VP-16, and 120 mg/kg cyclophosphamide. With a median follow-up of 30.5 months (range, 5-60 months), 25 patients are alive in continuous complete remission. Estimated disease-free survival at 5 years is 80.5%. Death was due to transplant-related toxicity (graft-versus-host disease and cytomegalovirus infection, graft-versus-host disease and pneumonia, sepsis and mucositis, respectively). None of the patients have relapsed. As demonstrated by the results of this analysis, the conditioning regimen busulfan/cyclophosphamide/etoposide is effective and well tolerated in patients with AML in first complete remission. Main nonhematological toxicities were mucositis and hepatotoxicity. The low mortality and relapse rate appears to justify allogeneic bone marrow transplantation for patients with AML in first complete remission who have an HLA-identical donor. Whether this regimen offers a substantial improvement in disease-free and overall survival over presently used regimens warrants further investigation.  (+info)

A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development. (8/3339)

SH2-containing Inositol Phosphatase (SHIP) is a 145 kD protein expressed in hematopoietic cells. SHIP is phosphorylated on tyrosine after receptor binding by several cytokines and has a negative role in hematopoiesis. We cloned a murine complementary DNA (cDNA) sequence for an isoform of SHIP with an internal 183 nucleotide deletion, encoding a protein 61 amino acids shorter than 145 kD SHIP. This deletion eliminates potential SH3-domain binding regions and a potential binding site for the p85 subunit of Phosphatidylinositol 3-Kinase. Using polyclonal anti-SHIP antibodies, we and others have previously observed a 135 kD SHIP isoform that is coexpressed with 145 kD SHIP. Here, we used monoclonal antibodies raised against the region deleted in the spliced form to show that the product of the novel spliced SHIP cDNA is antigenically identical to the 135 kD SHIP isoform. Like 145 kD SHIP, 135 kD SHIP expression was induced on differentiation of bone marrow cells. After macrophage colony-stimulating factor (M-CSF) stimulation of FDC-P1(Fms) myeloid cells, both 145 and 135 kD SHIP forms were tyrosine phosphorylated and could be coimmunoprecipitated with antibodies to Shc and Grb2. However, experiments showed only a weak association of 135 kD SHIP with p85. A potentially analogous 135 kD SHIP species also appears in human differentiated leukocytes.  (+info)

TY - JOUR. T1 - Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. AU - Kiser, M.. AU - McCubrey, J. A.. AU - Steelman, L. S.. AU - Shelton, J. G.. AU - Ramage, J.. AU - Alexander, R. L.. AU - Kucera, G. L.. AU - Pettenati, M.. AU - Willingham, M. C.. AU - Miller, M. S.. AU - Frankel, A. E.. N1 - Funding Information: This work was supported in part by the Leukemia and Lymphoma Society Grant No. 6114-99 (AEF), NIH CA76178 (AEF), NIH CA51025 (JAM) and the American Cancer Society Grant No. IRG-93-035-6 (GLK). The authors acknowledge the gift of SC-65461 and SC-50431 IL3 receptor agonist proteins from Dr Barbara Klein and Pharmacia, Inc. We thank Dr Douglas Case for input on statistical analyses.. PY - 2001. Y1 - 2001. N2 - We have developed an in vivo model of differentiated human acute myeloid leukemia (AML) by retroviral infection of the cytokine-dependent AML cell line TF-1 with the v-Src oncogene. When injected either intravenously or intraperitoneally into ...
Mitogen-activated protein kinases (MAPKs) are important transducers of external signals for cell growth, survival, and other cellular responses including cell differentiation. Several MAPK cascades are known with the MEK1/2-ERK1/2, JNK, and p38MAPKs receiving most attention, but the role of MEK5-ERK5 in intracellular signaling deserves more scrutiny, as this pathway transmits signals that can complement ERK/2 signaling. We hypothesized that the ERK5 pathway plays a role in the control of monocytic differentiation, which is disturbed in myeloid leukemia. We therefore examined the cellular phenotype and key molecular events which occur when human myeloid leukemia cells, acute (AML) or chronic (CML), are forced to differentiate by vitamin D derivatives (VDDs). This study was performed using established cell lines HL60 and U937, and primary cultures of blasts from 10 patients with ML. We found that ERK5 and its direct downstream target transcription factor MEF2C are upregulated by 1,25D in parallel ...
TY - JOUR. T1 - Proteomic analysis of the response to cell cycle arrests in human myeloid leukemia cells. AU - Ly, Tony. AU - Endo, Aki. AU - Lamond, Angus I.. N1 - Wellcome Trust 083524/Z/07/Z, 097945/B/11/Z, 073980/Z/03/Z, 08136/Z/03/Z, and 0909444/Z/09/Z Angus I Lamond; European Research Council HEALTH-F4-2010-257082 Angus I Lamond; Biotechnology and Biological Sciences Research Council BB/K003801/1 Angus I Lamond.. PY - 2015/1/2. Y1 - 2015/1/2. N2 - Previously, we analyzed protein abundance changes across a minimally perturbed cell cycle by using centrifugal elutriation to differentially enrich distinct cell cycle phases in human NB4 cells (Ly et al., 2014). In this study, we compare data from elutriated cells with NB4 cells arrested at comparable phases using serum starvation, hydroxyurea, or RO-3306. While elutriated and arrested cells have similar patterns of DNA content and cyclin expression, a large fraction of the proteome changes detected in arrested cells are found to reflect ...
Using deep sequencing (deepCAGE), the FANTOM4 study measured the genome-wide dynamics of transcription-start-site usage in the human monocytic cell line THP-1 throughout a time course of growth arrest and differentiation. Modeling the expression dynamics in terms of predicted cis-regulatory sites, we identified the key transcription regulators, their time-dependent activities and target genes. Systematic siRNA knockdown of 52 transcription factors confirmed the roles of individual factors in the regulatory network. Our results indicate that cellular states are constrained by complex networks involving both positive and negative regulatory interactions among substantial numbers of transcription factors and that no single transcription factor is both necessary and sufficient to drive the differentiation process ...
Description: Using deep sequencing (deepCAGE), the FANTOM4 study measured the genome-wide dynamics of transcription-start-site usage in the human monocytic cell line THP-1 throughout a time course of growth arrest and differentiation. Modeling the expression dynamics in terms of predicted cis-regulatory sites, we identified the key transcription regulators, their time-dependent activities and target genes. Systematic siRNA knockdown of 52 transcription factors confirmed the roles of individual factors in the regulatory network. Our results indicate that cellular states are constrained by complex networks involving both positive and negative regulatory interactions among substantial numbers of transcription factors and that no single transcription factor is both necessary and sufficient to drive the differentiation process. ...
Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: A report from the Childrens Cancer Group Academic Article ...
Data from a case-control study of childhood acute myeloid leukemia (AML) including 187 matched case-control pairs were examined for evidence of associations between parental cigarette smoking and alcohol consumption and the subsequent development of childhood AML. The cases were stratified by French-American-British morphology in order to evaluate potential differences in risk based on this classification system. There was little evidence of any association between cigarette smoking by parents during the index pregnancy and childhood AML. There was some evidence of an increased risk of AML among children who were diagnosed at or before 2 years of age and whose mothers reported consuming alcohol during their pregnancies (odds ratio, 3.00; 95% confidence interval, 1.23 to 8.35). This finding appeared to be especially pronounced for AML with a monocytic component (M4/M5) (odds ratio, 9.00; 95% confidence interval, 1.25 to 394.5), but a cautious interpretation of these data are advised because of ...
Cenpu - Mlf1ip (untagged) - Mouse myeloid leukemia factor 1 interacting protein (Mlf1ip), (10ug) available for purchase from OriGene - Your Gene Company.
Mutations in two metabolic enzymes-isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) have been responsible for 20 percent of all acute myeloid leukemias in the recent years
Background Description: Meisoindigo (Dian III; N-Methylisoindigotin; Natura-α) is a potential agent for acute myeloid leukemia. Meisoindigo is a synthetic modification of indirubin. It has been used for chronic myeloid leukemia in China with less toxicity. In the in vitro assay,PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/22614157. ...
Also known as: Acute myelocytic leukemia / Acute myeloid leukemia / Leukemia, Myeloid, Acute / Acute myelocytic leukaemia / Acute myeloblastic leukemia with failed remission / Leukaemia myeloblastic acute / AML / Non-lymphoblastic leukaemia acute / Non-lymphoblastic leukemia acute / Acute myeloid leukemia NOS / Myeloid leukaemia, acute / Leukaemias acute myeloid / Acute myeloblastic leukemia / Acute myeloblastic leukaemia / Leukemia myeloblastic acute / Acute granulocytic leukaemia / Acute granulocytic leukemia / Acute myeloid leukaemia / Myeloid leukemia, acute / Acute myeloid leukaemia NOS ...
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015 Summary Global Markets - Market research report and industry analysis - 9304064
The multifunctional E4F1 protein was originally identified as a cellular target of the E1A adenoviral oncoprotein. Although E4F1 is implicated in several key oncogenic pathways, its roles in tumorigenesis remain unclear. Using a genetically engineered mouse model of myeloid leukemia (histiocytic sarcomas, HS) based on the genetic inactivation of the tumor suppressor Ink4a/Arf locus, we have recently unraveled an unsuspected function of E4F1 in the survival of leukemic cells. In vivo, genetic ablation of E4F1 in established myeloid tumors results in tumor regression. E4F1 inactivation results in a cascade of alterations originating from dysfunctional mitochondria that induce increased reactive oxygen species (ROS) levels and ends in massive autophagic cell death in HS transformed, but not normal myeloid cells. E4F1 depletion also induces cell death in various human myeloid leukemic cell lines, including acute myeloid leukemic (AML) cell lines. Interestingly, the E4F1 protein is overexpressed in a large
CEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese population Long Su, SuJun Gao, XiaoLiang Liu, YeHui Tan, Lu Wang, Wei Li Cancer Center, The First Hospital, Jilin University, Changchun, Peoples Republic of China Background: This study was aimed to explore the clinical characteristics and prognoses of acute myeloid leukemia (AML) patients with CEBPA mutations. Patients and methods: Three hundred and forty-five patients with de novo AML were retrospectively analyzed with regard to CEBPA mutations, clinical characteristics, therapeutic responses, and long-term outcomes. Results: CEBPA mutations were detected in 59 patients (17.10%), with 47 cases harboring double mutations and 12 cases harboring single mutations. In those with a normal karyotype (NK), 44 cases (25.29%) were detected with CEBPA mutations. The following characteristics were observed in CEBPA-mutated patients: most (66.10%) of them were M1 or M2; they presented with higher peripheral white blood
Looking for information on Acute myelocytic leukemia? Medigest has all you need to know about Acute myelocytic leukemia - Symptoms and Signs, Causes, Treatments and definition
1. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U. et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-35 2. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD. et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233-39 3. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C. et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907-14 4. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J. et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and ...
Learn more about Chronic Myelocytic Leukemia at TriStar Southern Hills DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Chronic Myelocytic Leukemia (CML) - Epidemiology Forecast to 2025 Size and Share Published in 2017-09-20 Available for US$ 2750 at Researchmoz.us
Definition of acute myeloid leukemia in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is acute myeloid leukemia? Meaning of acute myeloid leukemia as a finance term. What does acute myeloid leukemia mean in finance?
Define Acute myeloid leukaemia. Acute myeloid leukaemia synonyms, Acute myeloid leukaemia pronunciation, Acute myeloid leukaemia translation, English dictionary definition of Acute myeloid leukaemia. Noun 1. acute myeloid leukemia - acute leukemia characterized by proliferation of granular leukocytes; most common in adolescents and young adults acute...
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017 Size and Share Published in 2017-06-30 Available for US$ 2500 at Researchmoz.us
Synonyms for Acute myeloid leukaemia in Free Thesaurus. Antonyms for Acute myeloid leukaemia. 1 synonym for acute myeloid leukemia: acute myelocytic leukemia. What are synonyms for Acute myeloid leukaemia?
TY - JOUR. T1 - Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons. AU - Lu, Frank Leigh. AU - Yu, Ching Chia. AU - Chiu, Huei Hsuan. AU - Liu, Hsingjin Eugene. AU - Chen, Shao Yin. AU - Lin, Shufan. AU - Goh, Ting Yi. AU - Hsu, Hsin Chih. AU - Chien, Chih Han. AU - Wu, Han Chung. AU - Chen, Ming Shan. AU - Schuyler, Scott C.. AU - Hsieh, Wu Shiun. AU - Wu, Mei Hwan. AU - Lu, Jean. PY - 2013/8. Y1 - 2013/8. N2 - Summary: Due to the development of drug resistance, the outcome for the majority of patients with acute myeloid leukemia (acute myelogenous leukemia; AML) remains poor. To prevent drug resistance and increase the therapeutic efficacy of treating AML, the development of new combinatory drug therapies is necessary. Sonic hedgehog (Shh) is expressed in AML biopsies and is essential for the drug resistance of cancer stem cells of AML. AML patients are frequently infected by bacteria ...
BACKGROUND: We investigated the spectrum, frequency, and risk factors for renal, gastrointestinal, and hepatic late adverse effects in survivors of childhood acute myeloid leukemia (AML) without relapse treated with chemotherapy alone according to three consecutive AML trials by the Nordic Society of Pediatric Hematology and Oncology (NOPHO).. METHODS: A population-based cohort of children treated for AML according to the NOPHO-AML-84, -88, and -93 trials included 138 eligible survivors of whom 102 (74%) completed a questionnaire and 104 (75%) had a clinical examination and blood sampling performed. Eighty-five of 94 (90%) eligible sibling controls completed a similar questionnaire. Siblings had no clinical examination or blood sampling performed.. RESULTS: At a median of 11 years (range 4-25) after diagnosis, renal, gastrointestinal, and hepatic disorders were rare both in survivors of childhood AML and in sibling controls, with no significant differences. Ferritin was elevated in 21 (21%) AML ...
A myeloid sarcoma (chloroma, granulocytic sarcoma, extramedullary myeloid tumor), is a solid tumor composed of immature white blood cells called myeloblasts. A chloroma is an extramedullary manifestation of acute myeloid leukemia; in other words, it is a solid collection of leukemic cells occurring outside of the bone marrow. The condition now known as chloroma was first described by the British physician A. Burns in 1811, although the term chloroma did not appear until 1853. This name is derived from the Greek word chloros (green), as these tumors often have a green tint due to the presence of myeloperoxidase. The link between chloroma and acute leukemia was first recognized in 1902 by Dock and Warthin. However, because up to 30% of these tumors can be white, gray, or brown rather than green, the more correct term granulocytic sarcoma was proposed by Rappaport in 1967 and has since become virtually synonymous with the term chloroma. Currently, any extramedullary manifestation of acute myeloid ...
ReportsnReports added a new report on The Acute Myelocytic Leukemia Market report that delivers the clean elaborated structure of the Report comprising each and every business-related information of the market at a global level. The in-depth study on the current state which focuses on the major drivers and restraint...
The CNS involvement of acute myeloid leukemia (AML) is more commonly manifest as meningeal involvement. Rarely it may present as intravascular tumor aggregates called granulocytic sarcoma which presents as intracranial hemorrhage. We are presenting a case of intracranial, intra-parenchymal granulocytic sarcoma (other names: chloroma, extramedullary myeloblastoma), presenting as acute hemiplegia without cerebral hemorrhage.
The cases, bibliography and associated comments included in this website and database have been provided by experts worldwide and reviewed by voluntary editorial working groups. The data and information is not guaranteed to be complete or to be fully up to date at any particular moment and it reflects the knowledge and views of the experts participating, not those of the World Health Organisation or the Italian National Transplant Centre.. ...
Among a series of myeloid leukemia cell lines, one (NFS-60) was found to have a rearrangement of the c-myb locus. The rearrangement involved the integration of a retrovirus into the region of the gene corresponding to the sixth exon of the avian c-myb locus. The insertion is associated with the production of a truncated RNA and the introduction of a terminator codon at the juncture of the long terminal repeat and the c-myb locus. The properties of the NSF-60 cells were compared with those of other myeloid cell lines, and the known sequence of differentiation induced by interleukin 3. Similar to other myeloid cell lines, the NFS-60 cells do not terminally differentiate in response to interleukin 3, granulocyte/macrophage, or granulocyte colony-stimulating factor suggesting that the cells are transformed with regard to their ability to differentiate. The NFS-60 cells are totally dependent on interleukin 3 for growth and maintenance of viability in vitro but also proliferate in response to ...
TY - JOUR. T1 - Retinoic acid-induced gene expression in normal and leukemic myeloid cells. AU - Murtaugh, Michael P.. AU - Dennison, Olivia. AU - Stein, Joseph P.. AU - Davies, Peter J.A.. PY - 1986/5/1. Y1 - 1986/5/1. UR - http://www.scopus.com/inward/record.url?scp=0022449402&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0022449402&partnerID=8YFLogxK. U2 - 10.1084/jem.163.5.1325. DO - 10.1084/jem.163.5.1325. M3 - Article. C2 - 2871126. AN - SCOPUS:0022449402. VL - 163. SP - 1325. EP - 1330. JO - Journal of Experimental Medicine. JF - Journal of Experimental Medicine. SN - 0022-1007. IS - 5. ER - ...
Acute myeloid leukemia is also called acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, acute non-lymphocytic leukemia, or sometimes just AML. It is most common in older people.
TY - JOUR. T1 - Detection of FUS-ERG chimeric transcript in two cases of acute myeloid leukemia with t(16;21)(p11.2;q22) with unusual characteristics. AU - Kim, Juwon. AU - Park, Tae Sung. AU - Song, Jaewoo. AU - Lee, Kyung A.. AU - Hong, Duk Jin. AU - Min, Yoo Hong. AU - Cheong, June Won. AU - Choi, Jong Rak. PY - 2009/10/15. Y1 - 2009/10/15. N2 - Reciprocal t(16;21)(p11;q22) is a rare chromosomal abnormality in acute myeloid leukemia (AML). The chimeric transcript FUS-ERG formed by this translocation which causes the replacement of RNA-binding domain of FUS (alias TLS) with the DNA-binding domain of ERG, and this event is thought to be responsible for leukemogenesis. Here we report two cases of AML with t(16;21)(p11.2;q22) showing unusual characteristics, and address the clinical, hematological, and molecular aspects of leukemia with t(16;21), along with a review of the literature.. AB - Reciprocal t(16;21)(p11;q22) is a rare chromosomal abnormality in acute myeloid leukemia (AML). The ...
Treatment for Acute Myeloid Leukemia in Sewri West, Mumbai. Find Doctors Near You, Book Appointment, Consult Online, View Doctor Fees, Address, Phone Numbers and Reviews. Doctors for Acute Myeloid Leukemia in Sewri West, Mumbai | Lybrate
Ortho-topolin riboside induced cell apoptosis through ERS pathway and inhibited DNMT1 activity in acute myeloid leukemia cells, Li Wang, YanHong Zhao, Jiao Cheng, FanLin Lin, YingY
Chronic myeloid leukemia is the tumour that occurs in blood cells and bone marrow, which is the soft parts inside bones where blood cells are produced.
CML progresses gradually. It is often slow growing for many years. Eventually, it may transform itself into acute myelogenous leukemia (AML). This is a more aggressive type of leukemia. It progresses much more rapidly and is more serious.. Cancer occurs when cells in the body become abnormal. They divide without control or order. Leukemia is cancer of the white blood cells and their parent cells. Leukemia cells do not function normally. They cannot do what normal blood cells do. In this case they can not fight infections. This means that the person is more likely to become infected with viruses or bacteria. The cancerous cells also overgrow the bone marrow. This forces other normal components, like platelets out. Platelets are needed to help the blood clot. As a results people with leukemia may bleed more easily.. ...
OBJECTIVE: To elucidate the regulatory effect of microRNA-34b on the occurrence of pediatric acute myeloid leukemia and the underlying mechanism. PATIENTS
This phase II trial is studying how well cediranib maleate works in treating patients with relapsed, refractory, or untreated acute myeloid leukemia or
S100A8 and S100A9 are calcium-binding proteins predominantly expressed by neutrophils and monocytes and play key roles in both normal and pathological inflammation. Recently, both proteins were found to promote tumor progression through the establishment of premetastatic niches and inhibit antitumor immune responses. Although S100A8 and S100A9 have been studied in solid cancers, their functions in hematological malignancies remain poorly understood. However, S100A8 and S100A9 are highly expressed in acute myeloid leukemia (AML), and S100A8 expression has been linked to poor prognosis in AML. We identified a small subpopulation of cells expressing S100A8 and S100A9 in AML mouse models and primary human AML samples. In vitro and in vivo analyses revealed that S100A9 induces AML cell differentiation, whereas S100A8 prevents differentiation induced by S100A9 activity and maintains AML immature phenotype. Treatment with recombinant S100A9 proteins increased AML cell maturation, induced growth arrest, and
The majority of acute myeloid leukemia (AML) patients have a poor response to conventional chemotherapy. The survival of chemoresistant cells is thought to depend on leukemia-bone marrow (BM) microenvironment interactions, which are not well understood. The CXCL12/CXCR4 axis has been proposed to support AML growth but was not studied at the single AML cell level. We recently showed that T-cell acute lymphoblastic leukemia (T-ALL) cells are highly motile in the BM; however, the characteristics of AML cell migration within the BM remain undefined. Here, we characterize the in vivo migratory behavior of AML cells and their response to chemotherapy and CXCR4 antagonism, using high-resolution 2-photon and confocal intravital microscopy of mouse calvarium BM and the well-established MLL-AF9-driven AML mouse model. We used the Notch1-driven T-ALL model as a benchmark comparison and AMD3100 for CXCR4 antagonism experiments. We show that AML cells are migratory, and in contrast with T-ALL, chemoresistant ...
Many studies have proposed that Siah1 genes are induced by p53 activation and may function as negative regulators of cell cycle progression, mediators of apoptosis, or tumor suppressors. Evidence for these hypotheses derives almost exclusively from gain-of-function studies in which p53 or Siah1 genes were overexpressed in transformed cell lines. In this study we have tested these models using a loss-of-function approach. We find no evidence to support a general role for Siah genes in a range of p53-mediated responses.. Previous reports have shown that transient overexpression of p53 in several different cell lines (32, 35) or activation of ts-p53 in immortalized MEF and mouse myeloid leukemic cell lines (1, 20, 43, 44, 47) induces Siah1 gene expression. Additionally, stable transfection of U937 cells with p21 increased SIAH1 mRNA levels (31, 32, 35) and enforced expression of SIAH1 or p21 induced the expression of an overlapping set of genes, supporting a model whereby Siah1 proteins function ...
Clinical trial for Acute myeloid leukemia | Acute Myelogenous Leukemia (AML) , Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML) a Cancer of the Blood
ABSTRACT Background: Chronic myeloid leukemia (CML) is a clonal malignant neoplasms of pluripotent hematopoietic stem cell described by the excessive proliferation of mature granulocytes and their precursors in the bone marrow and peripheral blood. It is characterized by the presence of Philadelphia chromosome, a translocation between chromosome 9 and 22 or BCR-ABL1 gene. Objectives: To evaluate clinical and hematological parameters in patients with chronic myeloid leukemia and to assess the risk stratification of these patients according to Sokal and European Treatment Outcome Study (EUTOS) scoring systems. Setting: This case series study conducted at Ibn-Sina Teaching Hospital/Outpatients Hematology Department from November 2019 to April 2020. Patients and methods: Total seventy patients with chronic myeloid leukemia included in this study. They involved 64 old cases and 6 new cases. The records of old cases were reviewed for clinical history, clinical examination, previous blood counts, bone marrow
Free Online Library: Acute myeloid leukemia diagnosis in the 21st century. by Archives of Pathology & Laboratory Medicine; Health, general Acute myelocytic leukemia Cytochemistry Cytogenetics
TY - JOUR. T1 - ETV6-LPXN fusion transcript generated by t(11;12)(q12.1;p13) in a patient with relapsing acute myeloid leukemia with NUP98-HOXA9. AU - Abe, Akihiro. AU - Yamamoto, Yukiya. AU - Iba, Sachiko. AU - Kanie, Tadaharu. AU - Okamoto, Akinao. AU - Tokuda, Masutaka. AU - Inaguma, Yoko. AU - Yanada, Masamitsu. AU - Morishima, Satoko. AU - Mizuta, Shuichi. AU - Akatsuka, Yoshiki. AU - Okamoto, Masataka. AU - Kameyama, Toshiki. AU - Mayeda, Akila. AU - Emi, Nobuhiko. PY - 2016/3/1. Y1 - 2016/3/1. N2 - ETV6, which encodes an ETS family transcription factor, is frequently rearranged in human leukemias. We show here that a patient with acute myeloid leukemia with t(7;11)(p15;p15) gained, at the time of relapse, t(11;12)(q12.1;p13) with a split ETV6 FISH signal. Using 3′-RACE PCR analysis, we found that ETV6 was fused to LPXN at 11q12.1, which encodes leupaxin. ETV6-LPXN, an in-frame fusion between exon 4 of ETV6 and exon 2 of LPXN, did not transform the interleukin-3-dependent 32D myeloid ...
We investigated whether octogenarian patients with acute myeloid leukemia enrolled onto Cooperative Group clinical trials and treated with intensive induction therapy could be cured, and whether karyotype and selected molecular markers had any prognostic significance in these patients. Among 138 patients with cytogenetic results, normal karyotype was the most common (47.1%) followed by complex karyotype (14.5%) and sole +8 (9.4%). Among these patients, the relapse-free survival (RFS) rate at 1 year was 37% and 13% at 3 years, and the respective overall survival (OS) rates were 24% and 8%. Whereas the 90 patients who survived beyond 30 days had the same RFS rates, their 1-year and 3-year OS rates were 36% and 11%, respectively. Of the 66 patients surviving beyond 30 days who could be classified into the European LeukemiaNet (ELN) Genetic Groups, those in the Intermediate-I Group had better OS than patients in the Adverse Group (P=.01). Among patients with cytogenetically normal acute myeloid ...
Treatment protocols for acute myeloid leukemia are provided below, including a general treatment approach and treatment recommendations for relapsed or refractory disease. General treatment approach for acute myeloid leukemia Fit patients (< 60-65 years, select patients up to age 75 y) receive intensive therapy.
Recognizes a 33kDa glycoprotein, identified as Nucleophosmin (NPM). It is predominantly localized in the nucleus of cells in most tissues. NPM is involved in ribosomal assembly and rRNA transport. It is an abundant protein that is highly phosphorylated by Cdc2 kinase during mitosis. This phosphoprotein moves between the nucleus and the cytoplasm.It is thought to be involved in several processes including regulation of the ARF/p53 pathway. A number of genes are fusion partners, in particular the anaplastic lymphoma kinase gene on chromosome 2. Mutations in exon 12 affecting the C-terminus of the protein are associated with an aberrant cytoplasmic location.Mutations in this gene are associated with acute myeloid leukemia.The antibody may be a useful aid for classification of acute myeloid leukemia.. ...
The FDA approved Idhifa (enasidenib) for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.
Drug tolerant leukemic cell subpopulations may explain frequent relapses in acute myeloid leukemia (AML), suggesting that these Relapse-Initiating Cells (RICs) persistent after chemotherapy represent bona fide targets to prevent drug resistance and relapse. We uncovered that the G-protein coup...
Cancers - Acute Myeloid Leukemia Support Group - Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukemia that affects both children and adults alike
Symptoms of acute myeloid leukemia can be divided into those caused by a deficiency of normally functioning cells, those due to the proliferation and infiltration of the abnormal leukemic cell populat... more
The percent of patients were shown as having a partial remission or better based on definitions of response in AML. Partial remission includes a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate. Complete remission includes presence of less than 5% blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. The percent and 95% exact confidence intervals will be calculated ...
Acute myeloid (myelogenous, myelocytic, myeloblastic) leukemia (AML) consists of a group of malignant disorders characterized by the replacement of normal bone marrow with abnormal, primitive hematopoietic cells. Although the cure rate has improved, treatments are associated with notable morbidity and mortality.
Hypermethylation of distal-less homeobox 4 ( DLX4) has been increasingly identified in several cancers. Our study was aimed to determine the role of DLX4 methylation in regulating DLX4expression and...
Quantitative and qualitative changes in cellular actin were followed during differentiation of a myeloid leukemia cell line, namely Ml, which was inducible with conditioned medium (CM). During 3 d of incubation with CM, when the Ml cells differentiated to macrophages and lost their mitotic activity, the actin content, F-actin ratio in total actin, and the actin synthesis showed an increase. A greater difference before and after differentiation was found in the ability of G-actin to polymerize. Actin harvested from CM-treated cells showed a greater ability to polymerize, depending on the increased concentration of MgCl2 and/or KCl and proteins, as compared with the actin from untreated Ml cells. Actin harvested from the Mml cell line, a macrophage line, had a particularly high polymerizability with or without CM treatment. In contrast, the actin from the D- subline, which is insensitive to CM, showed almost no polymerization. ...
The purpose of this study is to compare the results in older patients who have newly diagnosed or secondary acute myeloid leukemia (AML) and who are to
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML ...
Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Childhood acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells.
Sigma-Aldrich offers abstracts and full-text articles by [Meisheng Yu, Jishi Wang, Dan Ma, Shuya Chen, Xiaojing Lin, Qin Fang, Nana Zhe].
... is a type of leukemia affecting myeloid tissue. Types include: Acute myeloid leukemia Chronic myelogenous ... leukemia Acute megakaryoblastic leukemia Blastic plasmacytoid dendritic cell neoplasm Hematological malignancies Myeloblast ... Myeloid leukemia, Leukemia). ...
"Acute Myeloid Leukemia Staging". Retrieved 26 August 2011. Mihova D. "Leukemia acute - Acute myeloid leukemia with minimal ... Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal ... "Adult Acute Myeloid Leukemia Treatment". National Cancer Institute. 6 March 2017. Retrieved 19 December 2017. "Acute Myeloid ... and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB ...
... (aCML) is a type of leukemia. It is a heterogeneous disorder belonging to the group of ... Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 172, 1028- ... Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1031- ... The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and ...
This "one-to-one and first-degree equation" allowed Chronic Myeloid Leukemia to be controlled by imatinib. The defective BCR- ... Sawyers, Charles L. (1999-04-29). "Chronic Myeloid Leukemia". New England Journal of Medicine. 340 (17): 1330-1340. doi:10.1056 ...
... (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form ... This means that a little over 10% of all newly diagnosed leukemia cases will be chronic myeloid leukemia. The average risk of a ... Chronic Myeloid Leukemia at American Cancer Society CML information from The Leukemia & Lymphoma Society Chronic Myelocytic ... The American Cancer Society estimates that in 2014, about 5,980 new cases of chronic myeloid leukemia were diagnosed, and about ...
Acute erythrocyte leukemia is a rare form of acute myeloid leukemia (less than 5% of AML cases) where the myeloproliferation is ... Acute erythroid leukemia is rare, accounting for only 3-5% of all acute myeloid leukemia cases. One study estimated an ... These cases are now likely to instead be classified as acute myeloid leukemia with myelodysplasia-related changes or therapy- ... Naiem F, Rao PN (2009). "Acute Myeloid Leukemia". Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular ...
Löwenberg B, Downing JR, Burnett A (Sep 30, 1999). "Acute myeloid leukemia". N Engl J Med (Review). 341 (14): 1051-62. doi: ... Gassmann W, Winfried; Löffler H. (1995). "Acute megakaryoblastic leukemia". Leuk. Lymphoma. 18 Suppl 1: Leukemia and Lymphoma. ... Leukemia is a malignancy producing of white blood cells in bone marrow. It can be a serious disease if not treated early. ... These cancers include leukemias, lymphomas, and myelomas. These particular types of cancers can arise as defected mature cell ...
Forms of acute leukemia include: Acute myeloid leukemia Acute erythroid leukemia Acute lymphoblastic leukemia T-cell acute ... "Acute Myeloid Leukemia". The Lecturio Medical Concept Library. Retrieved 11 August 2021. Zuo Z, Polski JM, Kasyan A, Medeiros ... Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original diagnosis of leukemia. In ... lymphoblastic leukemia Adult T-cell leukemia/lymphoma (Precursor) T-lymphoblastic leukemia/lymphoma Blast crisis of chronic ...
... acute myeloid; 601626; FLT3 Leukemia, acute myeloid; 601626; KIT Leukemia, acute myeloid; 601626; LPP Leukemia, acute myeloid; ... JAK2 Leukemia, acute myeloid; 601626; MLF1 Leukemia, acute myeloid; 601626; NSD1 Leukemia, acute myeloid; 601626; SH3GL1 ... Leukemia, acute myeloid; 601626; AF10 Leukemia, acute myeloid; 601626; ARHGEF12 Leukemia, acute myeloid; 601626; CEBPA Leukemia ... acute myeloid; 601626; NUP214 Leukemia, acute myeloid; 601626; PICALM Leukemia, acute myeloid; 601626; RUNX1 Leukemia, acute ...
... is a rare form of acute myeloid leukemia where blasts are accompanied by abnormal basophils in all ... Duchayne, E.; H. Rubier; A. Robert; N. Dastugue (1999). "Diagnosis of acute basophilic leukemia". Leukemia & Lymphoma. 32 (3-4 ... "Molecular pathogenesis of chromosome 16 inversion in the M4E0 subtypes of acute myeloid leukemia". Blood. 85 (9): 2289-2302. ... Myeloid antigens are expressed. Diagnosis of poorly differentiated cases made by electron microscopy. May manifest basophil and ...
"Chemotherapy for Acute Myeloid Leukemia (AML)". www.cancer.org. Retrieved 2019-11-06. "Acute Myeloid Leukemia (AML) Subtypes ... Juvenile myelomonocytic leukemia "Acute Myeloid Leukemia - Signs and Symptoms". "eMedicine - Acute Myelogenous Leukemia : ... Acute myelomonocytic leukemia (AMML) is a form of acute myeloid leukemia that involves a proliferation of CFU-GM myeloblasts ... "Acute myelomonocytic leukemia (FAB AML M4)". www.pathologyoutlines.com. Retrieved 2019-11-06. "Acute Myeloid Leukemia (AML)". ...
Chronic myeloid leukemia often presents with a high number of immature granulocytes in the peripheral blood. Abnormal ... Basophilia and eosinophilia can occur along with other white blood cell abnormalities in chronic myeloid leukemia and other ... Emadi, Ashkan; Law, Jennie (2018). "Chronic Myeloid Leukemia (CML)". Merck Manuals Professional Edition. Archived from the ... occur in chronic myelomonocytic leukemia and acute leukemias of monocytic origin. Monocyte counts may be decreased ( ...
Melo JV (May 1996). "The molecular biology of chronic myeloid leukaemia". Leukemia. 10 (5): 751-756. PMID 8656667. "Gene entry ... "FDA approves Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia". ... ISBN 978-1-61519-197-0. "Chronic myeloid leukemia" (PDF). NCCN Clinical Practice Guidelines. National Cancer Comprehensive ... Burke BA, Carroll M (June 2010). "BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia". Leukemia ...
... chronic myeloid leukemia (CML); bipolar affective disorder; and other congenital disorders. In particular, the short stature ...
... acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)-as well as a number of less ... This divides leukemias into lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias: In lymphoblastic or ... especially acute myeloid leukemia), and Fanconi anemia is a risk factor for developing acute myeloid leukemia. Mutation in ... "Typical treatment of acute myeloid leukemia (except promyelocytic M3)". Detailed Guide: Leukemia - Acute Myeloid (AML). ...
"Chronic myeloid leukemia (CML)". Leukemia & Lymphoma Society. 2015-02-26. Archived from the original on 2019-09-22. Retrieved ... "Chronic myelogenous leukemia (CML) Chronic myelogenous leukemia (CML)". Medline Plus Medical Encyclopedia. U.S. National ... For example, ionizing radiation is one cause of chronic myelogenous leukemia, although most people with CML have not been ...
There have been reports of hairy cell leukemia, acute myeloid leukemia, and acute myeloblastic leukemia associated with ... Maloisel F, Oberling F (January 1992). "Acute myeloid leukemia complicating sarcoidosis". Journal of the Royal Society of ... Schiller G, Said J, Pal S (October 2003). "Hairy cell leukemia and sarcoidosis: a case report and review of the literature". ... Reich JM (January 1985). "Acute myeloblastic leukemia and sarcoidosis. Implications for pathogenesis". Cancer. 55 (2): 366-9. ...
"Chemotherapy for Chronic Myeloid Leukemia". cancer.org. American Cancer Society. February 22, 2016. Retrieved June 22, 2017. " ... "Chemotherapy for Childhood Leukemia". cancer.org. American Cancer Society. February 3, 2016. Retrieved June 22, 2017. " ... "Chemotherapy for Acute Lymphocytic Leukemia". cancer.org. American Cancer Society. February 18, 2016. Retrieved June 22, 2017 ... and is used to treat some leukemias, lymphomas, and childhood cancers, as well as several other types of cancer and some non- ...
February 2021). "Knockout of the RAS endoprotease RCE1 accelerates myeloid leukemia by downregulating GADD45b". Leukemia. 35 (2 ... Braun BS, Shannon K (April 2008). "Targeting Ras in myeloid leukemias". Clinical Cancer Research. 14 (8): 2249-52. doi:10.1158/ ... zinc-finger myeloid, nervy and DEAF1 (ZnF-MYND) domain; ubiquitin-associated (UBA) domain; CHORD-SGT1 (CS) domain; microtubule- ...
Patent 6,894,051 Experts in Chronic Myeloid Leukemia (May 2013). "The price of drugs for chronic myeloid leukemia (CML) is a ... "Cancer Stat Facts: Leukemia - Chronic Myeloid Leukemia (CML)". Cancer.gov. Retrieved 17 April 2020. Gambacorti-Passerini C, ... "Leukemia - Chronic Myeloid - CML: Statistics , Cancer.Net". 26 June 2012. Archived from the original on 12 November 2014. " ... Yin W, Penrod JR, Maclean R, Lakdawalla DN, Philipson T (November 2012). "Value of survival gains in chronic myeloid leukemia ...
"Chemotherapy for Chronic Myeloid Leukemia". cancer.org. American Cancer Society. 22 February 2016. Archived from the original ... "Chemotherapy for Childhood Leukemia". cancer.org. American Cancer Society. 3 February 2016. Archived from the original on 29 ... The drugs vinblastine and vincristine are vinca alkaloids, used to treat Hodgkin lymphoma, leukemia, and other cancers, were ... "Chemotherapy for Acute Lymphocytic Leukemia". cancer.org. American Cancer Society. 18 February 2016. Archived from the original ...
Myeloid leukemia is one target. Another study reported on an AI that was as good as doctors in identifying skin cancers. ...
Recent studies have shown that the mixed-lineage leukemia (MLL) gene causes leukemia by rearranging and fusing with other genes ... Garcia-Manero G (November 2008). "Demethylating agents in myeloid malignancies". Current Opinion in Oncology. 20 (6): 705-710. ... Leukemia related genes are managed by the same pathways that control epigenetics, signaling transduction, transcriptional ... Mandal SS (April 2010). "Mixed lineage leukemia: versatile player in epigenetics and human disease". The FEBS Journal. 277 (8 ...
December 2010). "DNMT3A mutations in acute myeloid leukemia". The New England Journal of Medicine. 363 (25): 2424-33. doi: ... Shih AH, Abdel-Wahab O, Patel JP, Levine RL (September 2012). "The role of mutations in epigenetic regulators in myeloid ... mutated genes identified in the Cancer Genome Atlas project DNMT3A mutations were most commonly seen in acute myeloid leukaemia ...
"What are the key statistics about acute myeloid leukemia?Key Statistics for Acute Myeloid Leukemia (AML)". American Cancer ... About 30,000 cases of myeloid leukemia occur in the United States each year. Some evidence suggests that workplace exposure to ... "Risk Factors for Acute Myeloid Leukemia (AML)". American Cancer Society. 2018-08-21. Archived from the original on 2019-04-23 ... "Risk Factors for Chronic Myeloid Leukemia". American Cancer Society. 2018-06-19. Archived from the original on 2018-12-12. ...
22 January 2016). "New drugs in acute myeloid leukemia". Annals of Oncology. 27 (5): 770-8. doi:10.1093/annonc/mdw015. PMC ... "Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia". ... as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy". Blood. ... Since leukemias typically develop multiple pathways of survival, lestaurtinib was studied in conjunction with traditional ...
"Childhood AML". Leukemia and Lymphoma Society. 2015-02-26. Retrieved 2018-12-13. "Childhood Acute Myeloid Leukemia/Other ... "Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ)-Patient Version". National Cancer Institute. 2018- ... Childhood leukemia is leukemia that occurs in a child and is a type of childhood cancer. Childhood leukemia is the most common ... Another type of acute leukemia is acute myelogenous leukemia (AML). AML accounts for most of the remaining cases of leukemia in ...
"Acute Myeloid Leukemia - Signs and Symptoms". Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD ... AMKL is commonly regarded as a subtype of acute myeloid leukemia (AML). More formally, it is classified under the AML-M7 ... Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally ... Gassmann W, Löffler H (1995). "Acute megakaryoblastic leukemia". Leukemia & Lymphoma. 18 Suppl 1: 69-73. doi:10.3109/ ...
"Chemotherapy for Acute Myeloid Leukemia (AML)". Vokes, E. E. (2010). "Induction Chemotherapy for Head and Neck Cancer: Recent ...
... acute myeloid leukemia, chronic myelomonocytic leukemia, case reports of chronic lymphocytic leukemia and large granular ... familial myelodysplastic syndrome/acute myeloid leukemia (i.e. familial MDS/AML); 3) chronic myelomonocytic leukemia (i.e. CMML ... Wang L, Du F, Zhang HM, Wang HX (July 2015). "Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 ... Churpek JE (December 2017). "Familial myelodysplastic syndrome/acute myeloid leukemia". Best Practice & Research. Clinical ...
One notable example is dasatinib which has been approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia ... Amsberg GK, Koschmieder S (2013). "Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia ... Breccia M, Salaroli A, Molica M, Alimena G (2013). "Systematic review of dasatinib in chronic myeloid leukemia". OncoTargets ... "HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias". ...
... such as in leukemia and lymphomas including hairy cell leukemia, chronic myeloid leukemia, nodular lymphoma, and cutaneous T- ...
... a characteristic abnormality in chronic myelogenous leukemia (CML) and rarely in some other leukemia forms. The BCR-ABL ... and gamma subunit immunoreceptor tyrosine-based activation motif in signaling of myeloid high affinity Fc receptor for IgG (Fc ... "Entrez Gene: ABL1 v-abl Abelson murine leukemia viral oncogene homolog 1". Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers ... Mutations in the ABL1 gene are associated with chronic myelogenous leukemia (CML). In CML, the gene is activated by being ...
However, counting CD34+ mononuclear cells may overestimate myeloid blasts in bone marrow smears due to hematogones (B ... Leukemia Research. 9 (1): 1-9. doi:10.1016/0145-2126(85)90016-5. PMID 3857402. Tindle RW. Katz F. Martin H. Watt D. Catovsky D ... Loken M. Shah V. Civin CI.. (1987). "Characterization of myeloid antigens on human bone marrow using multicolour ... Leukemia. 2 (12): 793-803. PMID 2462139. Nakamura Y, Komano H, Nakauchi H (February 1993). "Two alternative forms of cDNA ...
"The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells". EBioMedicine. ... Abedin MJ, Kashio Y, Seki M, Nakamura K, Hirashima M (May 2003). "Potential roles of galectins in myeloid differentiation into ... "Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia". Asian Pacific ...
J Biol Chem 279:8181-8189 (2004) Myeloid Leukemia Factor 1 associates with a novel heterogeneous nuclear ribonucleoprotein U- ... Leukemia 9:900-907 (1995) Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. ...
June 2007). "CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia". Proceedings of the National Academy ... and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia". Archives of Medical ... June 2011). "[CD96 expression on bone marrow mononuclear cells in 91 patients with acute leukemia]". Zhongguo Shi Yan Xue Ye ...
Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML). These ... March 2010). "The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting ... February 2015). "WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation". Molecular ...
May 2020). "Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic ...
"The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q". Proc. Natl ... It is thought that this genetic change is the key in development of this leukemia type. Human IL-3 was first cloned in 1986 and ... In addition, IL-3 stimulates proliferation of all cells in the myeloid lineage (granulocytes, monocytes, and dendritic cells), ... Sanchez X, Suetomi K, Cousins-Hodges B, Horton JK, Navarro J (1998). "CXC chemokines suppress proliferation of myeloid ...
Faust was diagnosed with Acute myeloid leukemia in 2009 and died on 23 May 2011. Faust was a father of three. Rugby League ... Deaths from acute myeloid leukemia, Deaths from cancer in Queensland, Rugby league players from Queensland). ...
Acute myeloid leukemia (AML) is a rapidly progressing disease that remains one of the most deadly blood cancers, killing more ... The Leukemia & Lymphoma Society, Our History The Leukemia & Lymphoma Society, History Beat AML "The Leukemia & Lymphoma Society ... "2017 Annual Report". Leukemia & Lymphoma Society. Retrieved 8 October 2018. About The Leukemia & Lymphoma Society "The Leukemia ... The name of the organization was later changed to the Leukemia Society, then to the Leukemia Society of America in the 1960s, ...
G6PD is hypomethylated at K403 in acute myeloid leukemia, SIRT2 activates G6PD to enhance NADPH production and promote leukemia ...
"FDA approves Mylotarg for treatment of acute myeloid leukemia". U.S. Food and Drug Administration (FDA) (Press release). 1 ... In the United States, gemtuzumab ozogamicin is indicated for newly diagnosed CD33-positive acute myeloid leukemia (AML) for ... 2001). "Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia". Clin Cancer Res. 7 (6): 1490-6. PMID ... that is used to treat acute myeloid leukemia. The most common grade 3 and higher adverse reactions that occurred during ...
... including Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Systemic Mastocytosis and Myelodysplastic Syndromes. These studies ... also termed cancer stem cell in the context of cancer and leukemic stem cell in leukemia contexts. Valent investigates the ...
Although myeloid cell production does not seem to decline with age, macrophages become dysregulated as a consequence of ... "PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia". ... April 2016). "Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic ...
Matsuoka, Masao (August 2003). "Human T-cell leukemia virus type I and adult T-cell leukemia". Oncogene. 22 (33): 5131-5140. ... as well as abnormalities in lymphoid and myeloid lineages. IDH2 mutations alter the function of IDH enzyme, leading to the ...
... for treatment of acute myeloid leukemia. In August 2019, the company announced it would acquire Cavion Inc. for up to ~$310 ... In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia. In January ...
19 July - Brendan Kehoe, 40, software developer and author, after a battle with acute myeloid leukemia. 4 August - Éamonn ...
Lymphoid and myeloid DCs evolve from lymphoid and myeloid precursors, respectively, and thus are of hematopoietic origin. By ... The disease may also present as a pDC leukemia, i.e. increased levels of malignant pDC in blood (i.e. >2% of nucleated cells) ... Three types of DCs have been defined in human blood: the CD1c+ myeloid DCs, the CD141+ myeloid DCs and the CD303+ plasmacytoid ... Blastic plasmacytoid dendritic cell neoplasm is a rare type of myeloid cancer in which malignant pDCs infiltrate the skin, bone ...
"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms." Nature 13 Aug 2009; 460, 904-909. Gondek LP, Tiu R, ... Correlation of prognosis with bone marrow cytogenetic finding in acute lymphoblastic leukemia Unclassified ALL is considered to ... Both deletion and 17p copy neutral LOH, were associated with a complex karyotype, a poor prognostic marker in myeloid ... 2000). "Genomic aberrations and survival in chronic lymphocytic leukemia". NEJM. 343 (26): 1910-6. doi:10.1056/ ...
... or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia ... in acute myelogenous leukemia, excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or ... This is because vinca alkaloids are rapidly deactivated in myeloid cells by their enzyme myeloperoxidase. So the vinca ... Chemotherapy regimens used in acute myeloid leukemia). ... than to the myeloid cell lines. Moreover, vinca alkaloids in ...
... in patients with advanced myeloid leukemias". Cancer. 118 (14): 3556-64. doi:10.1002/cncr.26664. PMC 4984525. PMID 22139909.{{ ...
"A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia". Blood. 91 (9): 3127-33. doi: ...
He died on November 23, 2012, from complications of acute myeloid leukemia. Hagman was born on September 21, 1931, in Fort ... Deaths from acute myeloid leukemia, Deaths from myelodysplastic syndrome, Film directors from California, Film directors from ... at Medical City Dallas Hospital in Dallas following complications from acute myeloid leukemia, after being interviewed for the ...
... and MOZ-CBP genes expressed in acute myeloid leukemia (AML), and the TMPRSS2-ETS chimera associated with overexpression of the ... For instance, gene fusion in chronic myelogenous leukemia (CML) leads to an mRNA transcript that encompasses the 5′ end of the ... breakpoint cluster region protein (BCR) gene and the 3′ end of the Abelson murine leukemia viral oncogene homolog 1 (ABL) gene ...
Since it was first identified in murine myeloid leukemia as a common site of retroviral integration into the chromosome, EVI1 ... "Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the ... in patients with myeloid leukemia". Genes, Chromosomes & Cancer. 36 (1): 80-9. doi:10.1002/gcc.10144. PMID 12461752. S2CID ... "Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines". Cell. 54 ( ...
... and thrombophilia as well as somatically acquired disorders including Myeloproliferative neoplasms and Acute myeloid leukemia ...
... caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia ...
Treatment options for adult acute myeloid leukemia (AML) include chemotherapy, radiation therapy, stem cell transplant, and ... Stages of Acute Myeloid Leukemia. Key Points. *Once acute myeloid leukemia (AML) has been diagnosed, tests are done to find out ... Acute Myeloid Leukemia Treatment (PDQ®)-Patient Version. On This Page. *General Information About Acute Myeloid Leukemia ... Sometimes leukemia cells form a solid tumor called a myeloid sarcoma. Myeloid sarcoma is also called extramedullary myeloid ...
Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Explore symptoms, inheritance, ... medlineplus.gov/genetics/condition/chronic-myeloid-leukemia/ Chronic myeloid leukemia. ... Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow. produces red ... Chronic myeloid leukemia occurs in about 1 in 555 individuals. It accounts for about 10 percent of all blood cell cancers ( ...
Acute myelogenous leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an ... encoded search term (Acute Myeloid Leukemia (AML)) and Acute Myeloid Leukemia (AML) What to Read Next on Medscape ... Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct ... TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group ...
Knowing the subtype of acute myeloid leukemia can be very important, as it can affect outlook and treatment options. Learn how ... Physician Data Query (PDQ). Adult Acute Myeloid Leukemia Treatment. 2018. Accessed at www.cancer.gov/types/leukemia/hp/adult- ... but are leukemias that have both lymphocytic and myeloid features. They are sometimes called mixed phenotype acute leukemias ( ... Acute Myeloid Leukemia (AML) Subtypes and Prognostic Factors. For most types of cancer, determining the stage (extent) of the ...
... for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated ... FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia * Resources for Information , Approved ... for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated ...
See what to know about treating relapsed or refractory acute myeloid leukemia, including chemotherapy, stem cell ... Acute Myeloid Leukemia: Treatment for Relapsed or Refractory Disease By Maxine Lipner ... While many people do well with initial treatment for acute myeloid leukemia (AML), some require more treatment. These people ... With a stem cell transplant, after bone marrow that has any leukemia cells is first destroyed, it is then replaced with stem ...
Acute Myeloid Leukemia (AML). What Is Leukemia?. Leukemia is a cancer that mostly affects white blood cells. White blood cells ... What Is Acute Myeloid Leukemia?. Acute myeloid leukemia (AML) happens when the body makes too many immature blood cells. These ... How Is Acute Myeloid Leukemia Diagnosed?. Doctors use special tests to check for leukemia. These include:. *Blood tests. Tests ... What Causes Acute Myeloid Leukemia?. Doctors dont know exactly what causes leukemia. But some things can make kids more likely ...
While advances in acute myeloid leukemia (AML) research have led to the development of a variety of novel treatments for the ... Clinical Challenges: Treating TP53-Mutated Acute Myeloid Leukemia. - Its of paramount importance that we do better for these ...
Despite the successes achieved with molecular targeted inhibition of the oncogenic driver Bcr-Abl in chronic myeloid leukemia ( ... Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia. Leukemia 34, 2635-2647 ( ... Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. ... Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501-10. ...
Leukemia - Acute Myeloid - AML - Childhood: Additional Resources. Approved by the Cancer.Net Editorial Board, 08/2019 ... Leukemia - Acute Myeloid - AML - Childhood - Questions to Ask the Health Care Team up ... Leukemia - Acute Myeloid - AML - Childhood Guide. Cancer.Net Guide. Leukemia - Acute Myeloid - AML - Childhood ... Leukemia - Acute Myeloid - AML - Childhood , *Leukemia - Acute Myeloid - AML - Childhood: Additional Resources ...
Diseases : Acute Myeloid Leukemia : CK(242) : AC(115). Pharmacological Actions : Antiproliferative : CK(6801) : AC(5032), ... Additional Keywords : Acute Myeloid Leukemia, Antiproliferative : CK(65) : AC(52), Apoptotic, Cell cycle arrest, ... activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. ...
FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia ... FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. Oct 29 ... for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated ... drug-resources/fda-alerts/2021/fda-approves-asciminib-for-philadelphia-chromosome-positive-chronic-myeloid-leukemia. (label- ...
Scientists have discovered the first compound which kills resistant cancer cells in acute myeloid leukemia but spares healthy ... What is Acute Myeloid Leukemia?. Acute myeloid leukemia (AML) is a type of leukemia which develops in cells that go onto ... Leukemia Cancer and Homeopathy Parkinsons Disease Surgical Treatment Chronic Myeloid Leukemia Acute Myeloid Leukemia Colorectal ... What Is Acute Myeloid Leukemia? - (https://www.cancer.org/cancer/acute-myeloid-leukemia/about/what-is-aml.html) ...
Assistance with the prescription drugs and biologics used in the treatment of Acute Myeloid Leukemia. Click here to see if you ... About Acute Myeloid Leukemia. Acute myeloid leukemia (AML) starts in the bone marrow (the soft inner part of certain bones, ... 1. You are being treated for Acute Myeloid Leukemia. Please make sure that HealthWell currently has a fund for your diagnosis/ ... "Myeloid" refers to the type of cell this leukemia starts from. Source: American Cancer Society ...
Acute myeloid leukemia - Homo sapiens (human) [ Pathway menu , Organism menu , Pathway entry , Download KGML , Show description ... Acute myeloid leukemia (AML) is a disease that is characterized by uncontrolled proliferation of clonal neoplastic cells and ... AML accounts for approximately 80% of all adult leukemias and remains the most common cause of leukemia death. Two major types ... Alterations in myeloid transcription factors governing hematopoietic differentiation provide second necessary event for ...
... is anticipated to gain lucrative growth over the forecast period owing to the rising incidences of acute myeloid leukemia (AML) ... Acute Myeloid Leukemia Therapeutics Market, Industry Report, 2025 GVR Report cover Acute Myeloid Leukemia Therapeutics Market ... The global acute myeloid leukemia therapeutics market is anticipated to gain lucrative growth over the forecast period as a ... The global acute myeloid leukemia therapeutics market is segregated into pipeline drugs, chemotherapy drugs, and chemotherapy ...
The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. The LLS mission: Cure leukemia, lymphoma ... The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest ...
Acute Myeloid Leukemia Leukemia Genetic and Rare Diseases Information Center resources: Myeloid Leukemia Acute Myeloid Leukemia ... Familial acute myeloid leukemia with mutated CEBPA Cytogenetically normal acute myeloid leukemia Core binding factor acute ... SEL24/MEN1703 in Patients With Acute Myeloid Leukemia. The safety and scientific validity of this study is the responsibility ... patients with diagnosis of Acute Myeloid Leukemia, all comers (completed) and bearing IDH1 or IDH2 mutation (open for ...
... hymeglusin may be attributed to the positive increase in the expression levels of HMGCS1 and multiple upregulated pro-leukemia ... Venetoclax is used for the priority treatment of elderly patients with acute myeloid leukemia (AML). Resistance or intolerance ... Venetoclax is used for the priority treatment of elderly patients with acute myeloid leukemia (AML). Resistance or intolerance ... IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell Stem Cell (2019) 24(1):153-65.e7. doi: ...
We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.. ...
Acute myeloid leukemia patients unable to find a matched donor for a life-saving stem cell transplant may soon have expanded ... An ongoing international multi-center Phase II study is set to include patients with acute myeloid leukemia, acute ... Acute Myeloid Leukemia Drug Granted Second Orphan Drug Status .social-ris-container { display: flex; justify-content: space- ... In earlier studies in which high-risk leukemia patients with poor prognosis received escalating doses of ATIR after a ...
Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients Anne-Pauline Bellanger. ... Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients. ...
... acute myeloblastic leukemia, acute granulocytic leukemia or acute nonlymphocytic leukemia. Pediatric cancer specialists at ... is a childhood bone marrow cancer also called acute myelogenous leukemia, ... Acute myeloid leukemia (AML), is a childhood bone marrow cancer also called acute myelogenous leukemia, acute myeloblastic ... AML is also called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia or acute nonlymphocytic ...
5 Lifestyle Tips For Living With Chronic Myeloid Leukemia (CML). It is estimated that there will be 8,950 new cases of men and ... Chronic Myeloid Leukemia Patients With History Of Malignancies Can Still Have Positive Outcomes With TKI Treatment. Researchers ... Lifestyle Changes After Chronic Myeloid Leukemia (CML) Treatment. Its hard readjusting to daily activities after undergoing ... are learning that a history of malignancies for people living with chronic myeloid leukemia (CML) doesnt mean theres a bad ...
... What are the symptoms of chronic myeloid leukemia (CML)?. Some people dont have any ...
Pharmacologic Inhibition of STAT5 in Acute Myeloid Leukemia. Leukemia 2018, 32, 1135-1146. [Google Scholar] [CrossRef][Green ... acute myeloid leukemia; tyrosine kinase inhibitor; FMS-like tyrosine kinase 3; targeted therapy; ponatinib; cabozantinib; WS6; ... Döhner, H.; Weisdorf, D.J.; Bloomfield, C.D. Acute Myeloid Leukemia. N. Engl. J. Med. 2015, 373, 1136-1152. [Google Scholar] [ ... Patients with Acute Myeloid Leukemia and an Activating Mutation in FLT3 Respond to a Small-Molecule FLT3 Tyrosine Kinase ...
Self help guide on how to live through Acute Myeloid Leukemia (AML). ... Thriving with Acute Myeloid Leukemia. Speaker Dr. Harry Erba, Survivor Debbie Beavers ... A study shows blood donors that do not have cancer including leukemia, 10% over 65 who donated find genetic changes commonly ...
Its important to keep your doctor updated on symptoms revolving around CML. Our specialists can help determine the proper treatment needed. Contact us today.
... S. Kartthik. ,1Prakas K ... In the article titled "An Unusual Cause of Bleeding in a Patient with Chronic Myeloid Leukemia Chronic Phase" [1], the author ... S. Kartthik, P. K. Mandal, and S. M. Abdullah, "An unusual cause of bleeding in a patient with chronic myeloid leukemia chronic ...
There are many treatment choices for acute myeloid leukemia. The best one for you depends on a number of factors. ... Acute Myeloid Leukemia (AML): Treatment Choices There are many treatment choices for acute myeloid leukemia (AML). Which one ... These medicines are used to treat a subtype of AML called acute promyelocytic leukemia (APL). Theyre not used for other types ...
  • The flow cytometry panel should be sufficient to distinguish AML (including acute promyelocytic leukemia), T-ALL (including early T-cell precursor leukemias), B-cell precursor ALL (B-ALL), and AL of ambiguous lineage for all patients diagnosed with AL. (medscape.com)
  • For patients with suspected acute promyelocytic leukemia (APL), ensure rapid detection of PML-RARA. (medscape.com)
  • On October 29, 2021, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and approved asciminib for adult patients with Ph+ CML in CP with the T315I mutation. (fda.gov)
  • While advances in acute myeloid leukemia (AML) research have led to the development of a variety of novel treatments for the disease, finding optimal strategies to treat AML patients with TP53 mutations remains a critical unmet need. (medpagetoday.com)
  • Despite the successes achieved with molecular targeted inhibition of the oncogenic driver Bcr-Abl in chronic myeloid leukemia (CML), the majority of patients still require lifelong tyrosine kinase inhibitor (TKI) therapy. (nature.com)
  • Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. (greenmedinfo.com)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703 and to further investigate its safety profile in patients with Acute Myeloid Leukemia. (clinicaltrials.gov)
  • Phase I/II, open-label, multi-center, dose escalation study to estimate the maximum tolerated dose of SEL24/MEN1703 in patients with Acute Myeloid Leukemia. (clinicaltrials.gov)
  • The clinical trial will investigate the safety profile and anti-leukemic activity of SEL24/MEN1703 in patients with Acute Myeloid Leukemia and that have no standard therapeutic options available. (clinicaltrials.gov)
  • Venetoclax is used for the priority treatment of elderly patients with acute myeloid leukemia (AML). (frontiersin.org)
  • Acute myeloid leukemia (AML) is a common hematological malignancy in adults, primarily in older patients. (frontiersin.org)
  • Acute myeloid leukemia patients unable to find a matched donor for a life-saving stem cell transplant may soon have expanded options for a mismatched donor. (pharmacytimes.com)
  • In earlier studies in which high-risk leukemia patients with poor prognosis received escalating doses of ATIR after a haploidentical stem cell transplant, the drug exhibited long-term safety, efficacy, and proof of concept in terms of the absence of life-threatening acute graft-versus-host-disease. (pharmacytimes.com)
  • An ongoing international multi-center Phase II study is set to include patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome to corroborate and extend the safety and efficacy results from the earlier studies. (pharmacytimes.com)
  • Fifteen patients had de novo AML, six AML with myelodysplasia-related changes, two AML with prior myeloproliferative neoplasm, one therapy-related myeloid neoplasm, and one myelodysplastic syndrome with excess blasts-2. (nih.gov)
  • Natural News ) Patients with chronic myeloid leukemia, who often suffer from anxiety, may find relief in bitter orange ( Citrus aurantium L. ) essential oil. (naturalnews.com)
  • The study, which was carried out by a team of researchers from Brazil examined the effect of bitter orange essential oil on the treatment of anxiety in patients with chronic myeloid leukemia. (naturalnews.com)
  • Based on these findings, the research team concluded that bitter orange essential oil has an anxiolytic effect, which suggests that it can be used to improve anxiety-related symptoms in patients with chronic myeloid leukemia. (naturalnews.com)
  • This week, we're covering the U.S. Food and Drug Administration (FDA) approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. (ascopost.com)
  • Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior response to standard chemotherapy treatment. (jci.org)
  • For patients with acute myeloid leukemia who are in a stage of complete remission and undergo stem cell transplantation, long-term survival outcomes are excellent. (fredhutch.org)
  • These individuals' baseline characteristics and outcomes were compared to those of 1,604 patients with DDX41 wild-type ( DDX41 WT ) AML, representing a prevalence of 5%, in 5 prospective Acute Leukemia French Association/French Innovative Leukemia Organization studies. (physiciansweekly.com)
  • Another example is Kaiser Permanente, which has decided that only one of three Kaiser institutions will treat patients with acute leukemia. (managedhealthcareexecutive.com)
  • BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. (eur.nl)
  • T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. (medscape.com)
  • In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang discuss the management of newly diagnosed older patients with acute myeloid leukemia (AML). (ascopost.com)
  • CD56 expression on the surface of leukemic cells in acute myeloid leukemia (AML) has been reported to correlate with higher rate of relapse and to be associated with poor outcome when patients are treated with conventional intensive chemotherapy. (ashpublications.org)
  • It is the first approved targeted cancer therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML), specifically, those screened by a complementary FDA-approved test and found to be carrying a mutated isocitrate dehydrogenase-1 (IDH1) gene. (pepid.com)
  • This is good news for about 6-10% of AML patients carrying this specific mutation who now have an acute myeloid leukemia treatment option. (pepid.com)
  • Patients can now avail of an acute myeloid leukemia treatment option that has been associated with complete remission and lessens the likelihood of needing blood transfusions. (pepid.com)
  • FDA Approves First Targeted Treatment for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have a Certain Genetic Mutation. (pepid.com)
  • FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation. (pepid.com)
  • This study aimed to characterize the psychological condition presented by the adult patients towards the Acute Myeloid Leukemia (AML). (bvsalud.org)
  • Regimens including venetoclax in myeloid BP or inotuzumab ozogamicin or blinatumomab in lymphoid BP might lead to deeper and longer responses, facilitating potentially curative allo-SCT for patients with CML-BP once CP is achieved. (bvsalud.org)
  • We present 2 cases of IFD and isavuconazole treatment failure in acute myeloid leukemia (AML) patients with prolonged neutropenia after hematopoietic stem-cell transplantation (SCT). (cdc.gov)
  • This project is being done to determine the highest safely tolerated dose of voruciclib in patients that have relapsed and/or refractory B cell type cancers or acute myeloid leukemia. (froedtert.com)
  • Ziftomenib, a potent and selective menin inhibitor, is currently in development for patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia. (wjbf.com)
  • The Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndromes (MDS) Moon Shot has opened two clinical trials to address a crucial problem for MDS patients: swift progression when their disease resists a crucial class of drugs called hypomethylating agents. (mdanderson.org)
  • Yin X , Huang H , Huang S , Xu A , Fan F , Luo S , Yan H , Chen L , Sun C , Hu Y . A Novel Scoring System for Risk Assessment of Elderly Patients With Cytogenetically Normal Acute Myeloid Leukemia Based on Expression of Three AQP1 DNA Methylation-Associated Genes. (wjgnet.com)
  • Here we investigated the effect of AdC on HLA-G expression in malignant hematopoetic cells isolated from patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (B-CLL). (elis.sk)
  • An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax. (targetedonc.com)
  • Neutropenic fever (NF) is a common and life -threatening complication of high- dose chemotherapy in patients with acute myeloid leukaemia (AML). (bvsalud.org)
  • A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center . (mdanderson.org)
  • Annamycin is currently in development for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML). (wkrg.com)
  • Acute Myeloid Leukaemia (AML) is a blood cancer, which affects the red blood cells in the bone marrow. (bioinformation.net)
  • The global acute myeloid leukemia therapeutics market is segregated into pipeline drugs, chemotherapy drugs, and chemotherapy regimens. (grandviewresearch.com)
  • In order to further prove a potential role for FOXM1 in AML chemoresistance, we induced an FLT3-ITD-driven myeloid neoplasm in a FOXM1-overexpressing transgenic mouse model and demonstrated significantly higher residual disease after standard chemotherapy. (jci.org)
  • Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. (medscape.com)
  • It accounts for about 10 percent of all blood cell cancers (leukemias). (medlineplus.gov)
  • OPB‑111077 is a novel, highly specific oral signal transducer and activator of transcription 3 inhibitor that has exhibited good efficacy against solid and blood cancers, including acute myeloid leukemia (AML), in preclinical models. (spandidos-publications.com)
  • DDX41 MutGL myeloid cancers may be regarded as a separate entity, according to recent findings, even when their exact presentation and prognosis were unknown. (physiciansweekly.com)
  • Although AML makes up only about 1 percent of all cancers, it is the second most common type of leukemia diagnosed, according to the American Cancer Society. (scitechdaily.com)
  • A total of 18,708 male cases of leukemia from the California Cancer Registry, including 1,703 cases usually employed in construction, were each matched with up to five controls from the same source who were diagnosed with cancers not thought to be related to exposures common in construction. (cdc.gov)
  • In this cohort, elevated rates of overall and site-specific cancers were observed, including digestive, oral, respiratory, and urinary cancers as well as leukemia (Daniels et al. (cdc.gov)
  • The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas. (ft.com)
  • Part 2: Expansion cohort: the main purpose of this part of the clinical trial is to assess the safety and anti-leukemia activity of SEL24/MEN1703 given at the highest tolerated dose in patient with relapsed/refractory Acute Myeloid Leukemia, either all comers as well as harboring IDH1/IDH2 mutations. (clinicaltrials.gov)
  • The optimal treatment regimen for relapsed/refractory acute myeloid leukemia (AML) is unknown. (centerwatch.com)
  • In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang treatment options for primary refractory FLT3-ITD-positive acute myeloid leukemia (AML). (ascopost.com)
  • Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells. (cancer.gov)
  • Leukemia cells can build up in the bone marrow and blood so there is less room for healthy white blood cells, red blood cells, and platelets. (cancer.gov)
  • Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). (medlineplus.gov)
  • In chronic myeloid leukemia, the bone marrow produces too many white blood cells. (medlineplus.gov)
  • With a stem cell transplant, after bone marrow that has any leukemia cells is first destroyed, it is then replaced with stem cells capable of developing into AML-free bone marrow. (verywellhealth.com)
  • With leukemia (loo-KEE-mee-uh), the bone marrow makes white blood cells that don't work. (kidshealth.org)
  • Acute myeloid leukemia (AML) starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but in most cases it quickly moves into the blood. (healthwellfoundation.org)
  • Acute myeloid leukemia (AML) is a disease that is characterized by uncontrolled proliferation of clonal neoplastic cells and accumulation in the bone marrow of blasts with an impaired differentiation program. (genome.jp)
  • Acute myeloid leukemia (AML), is a childhood bone marrow cancer also called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia or acute nonlymphocytic leukemia. (lvhn.org)
  • The leukemia cells can build up in the blood and bone marrow so there is less room for healthy cells. (lvhn.org)
  • Its purpose is to kill the leukemia cells in the blood and bone marrow. (lvhn.org)
  • People with chronic myeloid leukemia often experience anxiety-related symptoms due to the bone marrow aspiration procedure, which is a painful, invasive procedure used in hematological diseases causing anxiety?associated symptoms. (naturalnews.com)
  • Bone marrow examination revealed de novo acute myeloid leukemia. (go.jp)
  • Acute myeloid leukemia (AML) is a heterogeneous clonal hematopoietic progenitor cell disorder characterized by immature myeloid cell proliferation and bone marrow failure, exhibiting a spectrum of morphological, immunophenotypic, cytogenetic and molecular characteristics ( 1 ). (spandidos-publications.com)
  • These include acute myeloid leukemia (AML), which affects the hematopoietic cells [1] in the bone marrow. (inserm.fr)
  • Bone marrow failure due to acute myeloid leukemia (AML) is a significant factor behind the disease's high rate of morbidity and mortality. (scitechdaily.com)
  • Acute myeloblastic leukemia (AML) is a malignant bone marrow disease. (bvsalud.org)
  • Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors ( MYELOID PROGENITOR CELLS ) in the bone marrow and other sites. (bvsalud.org)
  • Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. (medscape.com)
  • A blood stem cell may become a myeloid stem cell or a lymphoid stem cell. (cancer.gov)
  • Acute lymphoblastic leukemia (ALL) / lymphoblastic lymphoma (LBL), also known as acute lymphocytic leukemia / lymphoma or acute lymphoid leukemia, is a cancer of precursor B-cell, T-cell, or other cell types in which immature lymphoid cells accumulate in blood, bone marrow, or other tissue. (logicalimages.com)
  • About half of people with chronic myeloid leukemia do not initially have any signs and symptoms and are diagnosed when a blood test is performed for another reason. (medlineplus.gov)
  • The presence of the Philadelphia chromosome provides a target for molecular therapies in people with chronic myeloid leukemia. (medlineplus.gov)
  • A study published in the journal Phytotherapy Research reported that breathing in bitter orange essential oil could reduce anxiety in people with chronic myeloid leukemia , suggesting that it has potential use as a natural treatment for anxiety. (naturalnews.com)
  • Chronic myeloid leukemia is one of the commonest hematological malignancies seen in clinical practice. (who.int)
  • The possibility that ROLVEDON acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which ROLVEDON is not approved, cannot be excluded. (rolvedon.com)
  • Many of the leukemia terms have undergone name changes as immunophenotypic and molecular biological techniques have made diagnosis more precise. (bvs.br)
  • Leukemia and 25.71% had Acute Myeloid Leukemia as the main diagnosis. (bvsalud.org)
  • The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (medscape.com)
  • Understanding the mechanisms underlying resistance to leukemia treatments and finding a way to resolve them are a central focus of the work of Inserm researcher Jean-Emmanuel Sarry and his team at the Cancer Research Center of Toulouse (Inserm/CNRS/Université de Toulouse III - Paul Sabatier). (inserm.fr)
  • Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. (cincinnatichildrens.org)
  • Leukemia is a cancer that mostly affects white blood cells. (kidshealth.org)
  • Leukemia is the most common type of cancer in children. (kidshealth.org)
  • Doctors carefully look at the cancer cells and figure out the type and subtype of the leukemia. (kidshealth.org)
  • Scientists at the Department of Medicine, Albert Einstein College of Medicine, NY have discovered a new molecule which kills resistant cancer cells in acute myeloid leukemia. (medindia.net)
  • Scientists discover that a molecule called BTSA1 can kill resistant cancer cells through apoptosis in acute myeloid leukemia but spare healthy cells. (medindia.net)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. (lls.org)
  • A study shows blood donors that do not have cancer including leukemia, 10% over 65 who donated find genetic changes commonly that are commonly found in AML. (nbmtlink.org)
  • Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML, is a kind of leukemia or cancer of the blood. (sprycel.com)
  • Ph+ CML is a kind of leukemia or cancer of the blood. (sprycel.com)
  • Researchers at the University of Chicago Medicine Comprehensive Cancer Center and their collaborators were interested in learning how mutant IDH2 drives the development of AML, and how the leukemia cells are able to regulate the production of 2-HG to promote spread and avoid cell death. (uchospitals.edu)
  • Leukemia groups several types of blood cancer that affect nearly 10,000 people each year in France . (inserm.fr)
  • Among those affected, the majority develop cancer , most often acute myelogenous leukemia (AML), and 90% develop aplastic anemia (the inability to produce blood cells) by age 40. (wikipedia.org)
  • Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. (medscape.com)
  • The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has been a model for cancer therapy development. (bvsalud.org)
  • One trial is the first conducted in leukemia of a rising type of cancer immunotherapy called immune checkpoint blockade. (mdanderson.org)
  • This puts the leukemia into remission. (lvhn.org)
  • It begins once the leukemia is in remission. (lvhn.org)
  • At present, the Leukemia & Lymphoma Society (LLS) estimates that there are 381,774 people in the U.S. who are either still battling leukemia or are in remission from it. (pepid.com)
  • AML is also called acute myelogenous leukemia and acute nonlymphocytic leukemia. (cancer.gov)
  • AML is also called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia or acute nonlymphocytic leukemia. (lvhn.org)
  • Priapism secondary to chronic myelogenous leukemia is an ischemic or low-flow process that is a urologic emergency. (acponline.org)
  • Ghiaur G, Wroblewski M, Loges S. Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. (medscape.com)
  • Researchers believe that additional genetic changes play a role in the progression of the chronic phase of chronic myeloid leukemia to the accelerated phase and blast crisis. (medlineplus.gov)
  • The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. (kegg.jp)
  • While many people do well with initial treatment for acute myeloid leukemia (AML) , some require more treatment. (verywellhealth.com)
  • This is important because treatment varies among different types of leukemia. (kidshealth.org)
  • Assistance with the prescription drugs and biologics used in the treatment of acute myeloid leukemia. (healthwellfoundation.org)
  • There are many treatment choices for acute myeloid leukemia (AML). (ahealthyme.com)
  • The immediate goal of treatment is to reduce the number of leukemia cells being produced in your body. (sprycel.com)
  • Glucocorticoid treatment can ameliorate effects of graft-versus-host disease and promote graft-versus-leukemia effects in pre-clinical models. (fredhutch.org)
  • In this webcast, experts examine advances in the treatment of acute myeloid leukemia (AML). (primeinc.org)
  • While the care and treatment of acute myeloid leukemia (AML) have greatly improved in recent years, overall survival remains low. (inserm.fr)
  • On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved the first acute myeloid leukemia treatment. (pepid.com)
  • Despite enduring complications and undergoing two transplants, Brown’s treatment was a success: he was cured both of his leukemia and HIV infection. (virology.ws)
  • Others - like Sweden's Meda - may also be relatively unaffected as - due to Bev Venue's position as the world's only supplier of the acute myeloid leukemia treatment Ceplene - mean the EMA has opted not to ask for a recall. (outsourcing-pharma.com)
  • Nevertheless treatment with 5-aza-2´- deoxycytidine enhanced HLA-G transcription and concomitantly HLA-G protein synthesis in some leukemia cells. (elis.sk)
  • A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax. (targetedonc.com)
  • Rising incidences of acute myeloid leukemia therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. (grandviewresearch.com)
  • The most frequent genetic susceptibility to myelodysplastic syndrome and acute myeloid leukemia (AML) is DDX41 germline mutations (DDX41 MutGL ). (physiciansweekly.com)
  • Pediatric acute myeloid leukemia is a heterogeneous illness with numerous subtypes primarily based on genetic, medical, transcriptional, and epigenomic elements. (chores4kids.com)
  • FRENCHTOWN, NJ / ACCESSWIRE / September 23, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Innovations in Acute Myeloid Leukemia Spotlight Event featuring Moleculin Biotech on Wednesday, September 28, 2022 at 11:00 AM ET. (wkrg.com)
  • Leukemia;2022 Oct 29. (bvsalud.org)
  • Limitations pertaining to current drug therapies available for acute myeloid leukemia are also expected to induce the need for improved and effective therapies, which will further drive the market. (grandviewresearch.com)
  • The advent of upcoming therapies including farnesyltransferase inhibitors, immunotoxins, alkylating agents, monoclonal antibodies , FMS-like tyrosine kinase 3 inhibitors, and multidrug-resistant modulators are anticipated to upsurge the acute myeloid leukemia (AML)market growth. (grandviewresearch.com)
  • Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies. (uchicago.edu)
  • In the article titled "An Unusual Cause of Bleeding in a Patient with Chronic Myeloid Leukemia Chronic Phase" [ 1 ], the author Dr. Souren Pal has been added to the authors list as he had involved in the initial patient care, i.e., clinical study partly. (hindawi.com)
  • S. Kartthik, P. K. Mandal, and S. M. Abdullah, "An unusual cause of bleeding in a patient with chronic myeloid leukemia chronic phase," Case Reports in Hematology , vol. 2019, Article ID 5674193, 5 pages, 2019. (hindawi.com)
  • In a latest research printed in Nature Communications , researchers used ribonucleic acid (RNA) sequence information to know the affiliation between inflammatory cytokines and poor outcomes of pediatric Acute Myeloid Leukemia (pAML). (chores4kids.com)
  • Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2021/fda-approves-asciminib-for-philadelphia-chromosome-positive-chronic-myeloid-leukemia . (hematology.org)
  • Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021 . (uchospitals.edu)
  • In AML, the myeloid stem cells usually become a type of immature white blood cell called myeloblasts (or myeloid blasts ). (cancer.gov)
  • Acute myeloid leukemia (AML) happens when the body makes too many immature blood cells. (kidshealth.org)
  • Chronic myeloid leukemia (CML) is caused by the Bcr-Abl translocation arising in the hematopoietic stem cell (HSC) compartment. (nature.com)
  • Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. (kegg.jp)
  • The mechanisms by which AML develops are not completely understood, but it is generally believed to begin in the hemopoietic stem cells or progenitors, which develop into myeloid cells and in turn go on to become red blood cells, white blood cells or platelets. (scitechdaily.com)
  • Myelodysplasticsyndrome (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases leading to an insufficient formation of functional blood cells. (nih.gov)
  • When his leukemia relapsed, Brown was subjected to a second stem cell transplant. (virology.ws)
  • The global acute myeloid leukemia therapeutics market is anticipated to gain lucrative growth over the forecast period as a consequence of rising incidences of acute myeloid leukemia (AML)and its relapse cases across the globe. (grandviewresearch.com)
  • Moreover, higher chances of early identification of leukemia cells, targeted therapy, and reduced chances of relapse of the acute myeloid leukemia are further expected to boost of the forecast period. (grandviewresearch.com)
  • Its purpose is to kill any remaining leukemia cells that may not be active but could begin to regrow and cause a relapse. (lvhn.org)
  • It has been shown to increase maturation of leukemia cells and reduce the number of leukemic cells in animal models. (uchospitals.edu)
  • These myeloblasts, or leukemia cells, are abnormal and do not become healthy white blood cells. (lvhn.org)
  • Leukemia may affect red blood cells, white blood cells, and platelets. (cancer.gov)
  • These abnormal white blood cells, red blood cells, or platelets are also called leukemia cells or blasts. (cancer.gov)
  • When they don't have enough platelets (PLATE-lits), kids with leukemia may bruise easily, get nosebleeds, or bleed for a long time after even a minor cut. (kidshealth.org)
  • Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. (medscape.com)
  • In some cases the distinctions between leukemias and lymphomas are now considered artificial, and so the nomenclature contains new descriptors such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA. (bvs.br)
  • The leukemia cells can spread outside the blood to other parts of the body, including the central nervous system (brain and spinal cord ), skin, and gums . (cancer.gov)
  • Sometimes leukemia cells form a solid tumor called a myeloid sarcoma . (cancer.gov)
  • In the 1970s, a group of French, American, and British leukemia experts divided AML into subtypes, M0 through M7, based on the type of cell the leukemia develops from and how mature the cells are. (cancer.org)
  • This was based largely on how the leukemia cells looked under the microscope after routine staining. (cancer.org)
  • There were, unfortunately, too many remaining leukemia cells. (verywellhealth.com)
  • By blocking this, it can allow the leukemia cells to better differentiate. (verywellhealth.com)
  • These cells, called myeloid (MYE-uh-loyd) blasts, can't mature into normal white blood cells. (kidshealth.org)
  • Because their white blood cells can't fight infections, kids with leukemia are more likely to get viral or bacterial infections. (kidshealth.org)
  • Doctors use these to rule out other causes of symptoms, or look for a mass of leukemia cells in the chest that can affect breathing or blood circulation. (kidshealth.org)
  • This discrepancy in sensitivity to hymeglusin may be attributed to the positive increase in the expression levels of HMGCS1 and multiple upregulated pro-leukemia genes in KG-1 cells. (frontiersin.org)
  • The histone deacetylase (HDAC) inhibitor panobinostat potentiates anthracycline and cytarabine cytotoxicity in acute myeloid leukemia (AML) cells. (nih.gov)
  • 2-HG blocks the maturation of white blood cells, driving the development of leukemia. (uchospitals.edu)
  • The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in primary acute myeloid leukemia (AML) cells, therefore representing a major target for drug development in this disease. (crick.ac.uk)
  • Mortality from leukemia was associated with duration of employment among styrene-exposed workers, such as those in the boatbuilding industry (Ruder et al. (cdc.gov)
  • [ 1 ] and French-American-British (FAB)2 classifications for acute lymphoblastic leukemia (ALL) are provided below. (medscape.com)
  • The WHO classifies ALL as B-lymphoblastic leukemia/lymphoma or T-lymphoblastic leukemia/lymphoma. (medscape.com)
  • LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia. (cincinnatichildrens.org)
  • Myeloid sarcoma is also called extramedullary myeloid tumor, granulocytic sarcoma, or chloroma. (cancer.gov)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • Leukemia and Lymphoma Society , 3 Mar. 2015, org/node/22231#Leukemia . (pepid.com)
  • For example, the acute promyelocytic leukemia (APL) subtype is often treated using drugs that are different from those used for other subtypes of AML. (cancer.org)
  • Other associations were limited to specific construction occupations, leukemia subtypes and/or racial/ethnic groups. (cdc.gov)
  • Although portal hypertension has been reportedly associated with myeloproliferative diseases, such as primary myelofibrosis, it has never been reportedly complicated with de novo acute myeloid leukemia. (go.jp)
  • AML is a particularly concerning form of leukemia in adults, as it progresses rapidly and has a 27.4% survival rate overall - the lowest number among all types of leukemia. (pepid.com)
  • Several types of leukemia, including acute myeloid leukemia (AML), have a strong association with it. (edgarsnyder.com)